Clinical Trials in Weinheim, Germany
6 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Breast Neoplasms
Novartis Pharmaceuticals3,250 enrolled267 locationsNCT06830720
Recruiting
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Breast CancerBreast NeoplasmsNeoplasm Metastasis
AstraZeneca800 enrolled107 locationsNCT05573893
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled917 locationsNCT06677060
Recruiting
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Female Breast Cancer
West German Study Group1,470 enrolled71 locationsNCT05792150
Recruiting
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
Cholangiocarcinoma
iOMEDICO AG100 enrolled7 locationsNCT06607302
Recruiting
Phase 2
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Advanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation+1 more
GBG Forschungs GmbH176 enrolled36 locationsNCT06201234
Recruiting
Phase 3
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
West German Study Group348 enrolled42 locationsNCT06081244
Recruiting
Phase 2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
HER2-positive Breast Cancer
GBG Forschungs GmbH170 enrolled29 locationsNCT05306041